Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Francois Baclesse
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women aged over 18
Invasive breast carcinoma confirmed histologically
Non-metastatic cancer
Surgery of the primary tumor performed (mastectomy or lumpectomy) and associated with an audit axillary (sentinel node and / or axillary dissection)
Patient should receive their last course of adjuvant chemotherapy (3 FEC and 3 Taxotere)
Patients not receiving the third course of Taxotere because of toxicities may be included in the fifth course of chemotherapy is the second of Taxotere
For the group Herceptin ®: HER2 overexpression without contraindication to treatment administration
For the control group: no indication for Herceptin ®
Radiation therapy and / or adjuvant hormonal therapy allowed
Free and informed consent signed
You may not be if
Women under 18 or over 60 years
Histology other than adenocarcinoma
Metastatic Breast Cancer
Chemotherapy neoadjuvant
Surgery of the primary tumor unrealized
Lack of adjuvant chemotherapy with Taxotere 3 FEC and 3
Patients with a history of malignancy within 5 years, outside of a basal cell cancer or cancer of the cervix treated and cured
Patient under guardianship or unable to give informed consent,
Pregnant or lactating
Patient unable to undergo a medical for geographical, social or psychopathological
Clareo Health | Experience of the Patient Treated With Trastuzumab (Herceptin ®) as Adjuvant for Breast Cancer
